Novel, experimental treatment for emphysema may offer promising results for patients looking to breathe easier ...
Zacks Investment Research on MSN
GSK gets EU approval for expanded use of Nucala in COPD
GSK plc GSK announced that the European Commission has approved its blockbuster respiratory drug, Nucala (mepolizumab), for ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
The primary finding from the clinical trials for the COPD biologics is reduced annual exacerbations by 30% (BOREAS trial) and 34% (NOTUS trial). In the BOREAS trial, in addition to reduced ...
Stopping long-acting inhalers for chronic obstructive pulmonary disease (COPD) can lead to a sharp rise in flare-ups for ...
This publication aims to improve treatment and care for adults with chronic obstructive pulmonary disease (COPD). It provides commissioners with strategies and recommendations for frontline care, ...
NICE has estimated that around 40% of people with COPD have elevated blood levels of eosinophils and, if half the eligible ...
Do vitamin K antagonists affect COPD outcomes? New cohort data explore exacerbation and mortality risk compared with DOACs.
Australia: A new study has found that among people with chronic obstructive pulmonary disease (COPD), beta-blocker therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results